Low-dose Interleukin-2 for the Reduction of Vascular Inflammation in Acute Coronary Syndromes - IVORY
Status:
Recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
Acute coronary syndromes (ACS) result from coronary plaque(s) disruption, which initiates a
thrombotic process leading to partial or complete obstruction of the vessel lumen with
subsequent myocardial ischaemia and necrosis. The mainstay of treatment is currently focused
on the re-establishment and maintenance of coronary artery patency using anti-platelets and
anticoagulants with or without mechanical dilatation and stenting of the culprit artery.
Despite important advances in management, ACS still carries a risk of substantial morbidity
and mortality. The improved efficacy of novel anti-platelet and anticoagulant agents have
been limited by increased risk of haemorrhagic events. Future breakthroughs in management are
most likely to arise from targeting other relevant pathophysiological pathways. Particularly,
the immune response which is an important process that has been neglected in the management
of patients with ACS.
In this trial the investigators investigate the efficacy of low dose IL-2 compared with
placebo in patients with ACS.
Phase:
Phase 2
Details
Lead Sponsor:
Cambridge University Hospitals NHS Foundation Trust